Composition for diagnosis or prediction of metabolic syndrome or group at high risk of expression of blood ceramide
The present invention relates to a composition for diagnosing or predicting a metabolic syndrome and a composition for predicting a group at high risk of expression of blood ceramide and to a single nucleotide polymorphism (SNP), derived through a genome wide association study (GWAS), capable of predicting metabolic syndrome and a group at high risk of expression of blood ceramide, which is a risk factor for metabolic syndrome. When used, a SNP marker derived by the present invention makes it possible to diagnose or predict metabolic syndrome and to predict a group at high risk of expression of blood ceramide, whereby patients suffering from the metabolic syndrome caused by a high expression of blood ceramide can be effectively diagnosed and managed. On the basis of these effects, the present invention can find wide applications in the pharmaceutical industry, etc.
1 . A method for diagnosing and treating metabolic syndrome in a subject, comprising:
(a) obtaining a sample comprising nucleic acids from a subject;
(b) assaying the sample to detect the presence of G allele at SNP rs75397325;
(c) diagnosing the subject as having metabolic syndrome based on the detection of the G allele at SNP rs75397325; and
(d) administering an effective dose of a metabolic syndrome therapeutic agent to the subject diagnosed as having the metabolic syndrome in step (c),
wherein the metabolic syndrome therapeutic agent is at least one selected from the group consisting of pitavastatin, amlodipine besylate, losartan, carvedilol, lovastatin, pravastatin, simvastatin, fluvastatin, atorvastatin, rosuvastatin, fenofibrate, gemfibrozil, bezafibrate, pravafenix, ezetimibe, niacin, probucol, orlistat, lorcaserin, diethylpropion, phentermine, mazindol, phendimetrazine, lorcaserin, liraglutide, nicotinic acid and acipimox.
2 . The method for diagnosing and treating the metabolic syndrome of claim 1 , wherein step (b) further includes detecting, from the analysis sample of step (a), at least one polynucleotide selected from the group consisting of
a polynucleotide consisting of 10 to 100 consecutive DNA sequences including a single nucleotide polymorphism in which a base at position 101 is A or G in a polynucleotide represented by SEQ ID NO: 3;
a polynucleotide consisting of 10 to 100 consecutive DNA sequences including a single nucleotide polymorphism in which a base at position 101 is C, A or T in a polynucleotide represented by SEQ ID NO: 4;
a polynucleotide consisting of 10 to 100 consecutive DNA sequences including a single nucleotide polymorphism in which a base at position 101 is T or C in a polynucleotide represented by SEQ ID NO: 5;
a polynucleotide consisting of 10 to 100 consecutive DNA sequences including a single nucleotide polymorphism in which a base at position 101 is G or A in a polynucleotide represented by SEQ ID NO: 6;
a polynucleotide consisting of 10 to 100 consecutive DNA sequences including a single nucleotide polymorphism in which a base at position 101 is C or T in a polynucleotide represented by SEQ ID NO: 7;
a polynucleotide consisting of 10 to 100 consecutive DNA sequences including a single nucleotide polymorphism in which a base at position 101 is C or T in a polynucleotide represented by SEQ ID NO: 8;
a polynucleotide consisting of 10 to 100 consecutive DNA sequences including a single nucleotide polymorphism in which a base at position 101 is C or T in a polynucleotide represented by SEQ ID NO: 9;
a polynucleotide consisting of 10 to 100 consecutive DNA sequences including a single nucleotide polymorphism in which a base at position 101 is C, G or T in a polynucleotide represented by SEQ ID NO: 10;
a polynucleotide consisting of 10 to 100 consecutive DNA sequences including a single nucleotide polymorphism in which a base at position 101 is A or C in a polynucleotide represented by SEQ ID NO: 11; and
a polynucleotide consisting of 10 to 100 consecutive DNA sequences including a single nucleotide polymorphism in which a base at position 101 is A, C, G or T in a polynucleotide represented by SEQ ID NO: 12.
3 . The method for diagnosing and treating the metabolic syndrome of claim 2 , wherein the subject diagnosed with the metabolic syndrome is a subject at high risk of increased levels of blood ceramide.
4 . The method for diagnosing and treating the metabolic syndrome of claim 1 , wherein the subject diagnosed with the metabolic syndrome is a subject at high risk of increased levels of blood ceramide, and wherein the ceramide is any one selected from the group consisting of C16 dihydroceramide, C18 dihydroceramide, C24 dihydroceramide, C24:1 dihydroceramide, C16 ceramide, C18 ceramide and C20 ceramide.
5 . The method for diagnosing and treating the metabolic syndrome of claim 1 , wherein the metabolic syndrome is characterized by at least three symptoms selected from the group consisting of central obesity, hyperglycemia, hypertriglyceridemia, hyperlipidemia and hypertension.